Development of novel AAV capsids for gene therapy
Revvity’s gene delivery team, where SIRION Biotech’s expertise lives on, has been partnering with pharma and biotech organizations for many years to provide improved viral vectors using our adeno-associated virus (AAV) engineering and development capabilities.
We work very closely with our clients, providing expertise, ideas, and innovation throughout the AAV engineering and development process – acting as an extension of the client’s team and always keeping their end goal in mind. We regularly report on progress to keep them well-informed, and draw on our many years of experience in adeno-associated virus manufacturing and development to help deliver quality viral vectors in a timely manner. Our collaborative and consultative approach also includes identifying and managing technology partners in the form of professional alliance management.
So, if you’re looking for an experienced, collaborative and innovative partner to develop improved viral vectors, which can help to deliver therapeutic genes to the target, reduce dosages and mitigate side effects, look no further.
AAV capsid directed evolution
To optimize adeno-associated virus tropism, our RNA-driven technology uses a directed evolution approach via capsid randomization. This technology is made available through the partnership and license agreements between Revvity and Heidelberg University in Germany. Under these agreements, Revvity works closely with Prof. Dr. Dirk Grimm, a pioneer in AAV capsid evolution.
AAV directed capsid evolution entails:
- Iterative in vivo screenings of recombinant AAV (rAAV) libraries harboring randomized peptide insertion libraries or AAV shuffled variants or combinations thereof.
- In vivo biodistribution analysis of enriched barcoded AAVs.
- Adeno-associated virus lead candidates are identified using advanced single cell-based analysis, with data collections obtained from next generation sequencing and PCR techniques from transduced tissue.
AAV rational design – nanobody targeting
Highly specific nanobodies are the basis of a novel rational design strategy that allows direct targeting of a surface protein of interest.
This technology can be implemented separately or in combination with directed evolution of AAV capsids to further enhance cell or tissue tropism and minimize off-target effects.
Please contact us to learn more about our adeno-associated virus capsid development capabilities and to speak to our specialist team.
For research use only. Not for use in diagnostic procedures.
